Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



FHD-286 in Subjects With Advanced Hematologic Malignancies

Multiple Cancer Types

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with advanced hematologic malignancies, specifically relapsed or refractory (R / R) acute myeloid leukemia (AML) or R / R myelodysplastic syndromes (MDS).
Leukemia, Myelodysplastic Syndrome, Phase I
I
Savona, Michael
NCT04891757
VICCHEMP2138

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: